Predicting the probable outcome of treatment in HCV patients

Therapeutic Advances in Gastroenterology

Volumn 2, Issue 5, 2009, Pages 287-302

  Navaneethan, Udayakumar ^a   Kemmer, Nyingi ^a   Neff, Guy W ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Hepatitis C; Pegylated interferon; Predicting outcome; Ribavirin; Sustained virological response

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HLA ANTIGEN; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

AGE DISTRIBUTION; ALCOHOL CONSUMPTION; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; ETHNICITY; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEREDITY; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER FIBROSIS; NONHUMAN; OBESITY; PATHOGENESIS; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; POINT OF CARE TESTING; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

EID: 77953393036     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X09339079     Document Type: Review

References (138)

1. Adinolfi, L.E., Ingrosso, D., Cesaro, G., Cimmino, A., D'Anto‘, M., Capasso, R. et al. (2005) Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology 41: 995-1003.
2. Alfaleh, F.Z., Hadad, Q., Khuroo, M.S., Aljumah, A., Algamedi, A., Alashgar, H. et al. (2004) Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 24: 568-574.
3. Anand, B.S., Currie, S., Dieperink, E., Bini, E.J., Shen, H., Ho, S.B. et al. (2006) Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 130: 1607-1616.
4. Andriulli, A., Mangia, A., Iacobellis, A., Ippolito, A., Leandro, G. and Zeuzem, S. ( 2008) Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 28: 397-404.
5. Armstrong, G.L., Wasley, A., Simard, E.P., Mcquillan, G.M., Kuhnert, W.L. and Alter, M.J. ( 2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144: 705-714.
6. Asselah, T., Bieche, I., Narguet, S., Sabbagh, A., Laurendeau, I., Ripault, M.P. et al. (2008) Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 57: 516-524.
7. Barbaro, G., Di Lorenzo, G., Ribersani, M., Soldini, M., Giancaspro, G., Bellomo, G. et al. (1999) Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype. J Hepatol 30: 774-782.
8. Bedossa, P. and Poynard, T. ( 1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24: 289-293.
9. Benhamou, Y., Bochet, M., Di Martino, V., Charlotte, F., Azria, F., Coutellier, A. et al. (1999) Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30: 1054-1058.
10. Berg, T., Sarrazin, C., Herrmann, E., Hinrichsen, H., Gerlach, T., Zachoval, R. et al. (2003) Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37: 600-609.
11. Berg, T., von Wagner, M., Nasser, S., Sarrazin, C., Heintges, T., Gerlach, T. et al. (2006) Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa- 2a plus ribavirin. Gastroenterology 130: 1086-1097.
12. Bonkovsky, H.L., Naishadham, D., Lambrecht, R.W., Chung, R.T., Hoefs, J.C., Nash, S.R. et al. (2006) Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 131: 1440-1451.
13. Bressler, B.L., Guindi, M., Tomlinson, G. and Heathcote, J. ( 2003) High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38: 639-644.
14. Castera, L., Hezode, C., Roudot-Thoraval, F., Bastie, A., Zafrani, E.S., Pawlotsky, J.M. et al. (2003) Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 52: 288-292.
15. Centers for Disease Control and Prevention ( 2005). Hepatitis Surveillance Report No. 60. Atlanta, US Dept of Health and Human Services, Centers for Disease Control and Prevention.
16. Charlton, M.R., Pockros, P.J. and Harrison, S.A. ( 2006) Impact of obesity on treatment of chronic hepatitis C. Hepatology 43: 1177-1186.
17. Chen, L., Borozan, I., Feld, J., Sun, J., Tannis, L.L., Coltescu, C. et al. (2005) Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128: 1437-1444.
18. Cheung, R.C., Currie, S., Shen, H., Ho, S.B., Bini, E.J., Anand, B.S. et al. (2005) Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 100: 2186-2193.
19. Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W. and Houghton, M. ( 1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359-362.
20. Conjeevaram, H.S., Kleiner, D.E., Everhart, J.E., Hoofnagle, J.H., Zacks, S., Afdhal, N.H. et al. (2007) Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 45: 80-87.
21. Conjeevaram, H.S., Fried, M.W., Jeffers, L.J., Terrault, N.A., Wiley-Lucas, T.E., Afdhal, N. et al. (2006) Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131: 470-477.
22. Dalgard, O., Bjoro, K., Hellum, K.B., Myrvang, B., Ritland, S., Skaug, K. et al. (2004) Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 40: 1260-1265.
23. Dalgard, O., Bjoro, K., Ring-Larsen, H., Bjornsson, E., Holberg-Petersen, M., Skovlund, E. et al. (2008) Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 47: 35-42.
24. Davis, G.L., Wong, J.B., McHutchison, J.G., Manns, M.P., Harvey, J. and Albrecht, J. ( 2003) Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 38: 645-652.
25. Dienstag, J.L. and McHutchison, J.G. ( 2006) American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 130: 231-264.
26. Eguchi, Y., Mizuta, T., Yasutake, T., Hisatomi, A., Iwakiri, R., Ozaki, I. et al. (2006) High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. World J Gastroenterol 12: 556-560.
27. European Association for the Study of the Liver. ( 1999) International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 30: 956-961.
28. Everson, G.T., Hoefs, J.C., Seeff, L.B., Bonkovsky, H.L., Naishadham, D., Shiffman, M.L. et al. (2006) Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 44: 1675-1684.
29. Fargion, S., Fracanzani, A.L., Sampietro, M., Molteni, V., Boldorini, R., Mattioli, M. et al. (1997) Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol 9: 497-503.
30. Feld, J.J., Nanda, S., Huang, Y., Chen, W., Cam, M., Pusek, S.N. et al. (2007) Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 46: 1548-1563.
31. Ferenci, P., Fried, M.W., Shiffman, M.L., Smith, C.I., Marinos, G., Gonçales, Jr F.L. et al. (2005) Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 43: 425-433.
32. Ferenci, P., Laferl, H., Scherzer, T.M., Gschwantler, M., Maieron, A., Brunner, H. et al. (2008) Peginterferon Alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology.
33. Fracanzani, A.L., Conte, D., Fraquelli, M., Taioli, E., Mattioli, M., Losco, A. et al. (2001) Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 33: 647-651.
34. Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Gonçales, Jr F.L. et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
35. Fried, M.W., Hadziyannis, S.J., Shiffman, M., Messinger, D. and Zeuzem, S. ( 2008) Rapid viral response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis c virus infection. J Hepatol 48(Suppl.2): 5A.
36. Gehrke, S.G., Stremmel, W., Mathes, I., Riedel, H.D., Bents, K. and Kallinowski, B. ( 2003) Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype. J Mol Med 81: 780-787.
37. Goodman, Z.D. and Ishak, K.G. ( 1995) Histopathology of hepatitis C virus infection. Semin Liver Dis 15: 70-81.
38. Hadziyannis, S.J., Sette, Jr H., Morgan, T.R., Balan, V., Diago, M., Marcellin, P. et al. (2004) Peginterferon-alpha2a and ribavarin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavarin dose. Ann Intern Med 140: 346-355.
39. Harris, M.I., Flegal, K.M., Cowie, C.C., Eberhardt, M.S., Goldstein, D.E., Little, R.R. et al. (1998) Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 21: 518-524.
40. Harrison, S.A. ( 2006) Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 40: 68-76.
41. Hasan, F., Asker, H., Al Khaldi, J., Siddique, I., Al Ajmi, M., Owaid, S. et al. (2004) Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 99: 1733-1737.
42. Hepburn, M.J., Hepburn, L.M., Cantu, N.S., Lapeer, M.G. and Lawitz, E.J. ( 2004) Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 117: 163-168.
43. Herrmann, E., Lee, J.H., Marinos, G., Modi, M. and Zeuzem, S. ( 2003) Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37: 1351-1358.
44. Hickman, I.J., Clouston, A.D., MacDonald, G.A., Purdie, D.M., Prins, J.B., Ash, S. et al. (2002) Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 51: 89-94.
45. Hickman, I.J., Powell, E.E., Prins, J.B., Clouston, A.D., Ash, S., Purdie, D.M. et al. (2003) In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 39: 1042-1048.
46. Hofer, H., Osterreicher, C., Jessner, W., Penz, M., Steindl-Munda, P., Wrba, F. et al. (2004) Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. J Hepatol 40: 1018-1022.
47. Huang, H., Shiffman, M.L., Cheung, R.C., Layden, T.J., Friedman, S., Abar, O.T. et al. (2006) Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 130: 1679-1687.
48. Huang, Y., Feld, J.J., Sapp, R.K., Nanda, S., Lin, J.H., Blatt, L.M. et al. (2007) Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology 132: 733-744.
49. Hughes, C.A. and Shafran, S.D. ( 2006) Chronic hepatitis C virus management: 2000-2005 update. Ann Pharmacother 40: 74-82.
50. Ishak, K., Baptista, A., Bianchi, L., Callea, F., de Groote, J., Gudat, F. et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699.
51. Jacobs, J.M., Diamond, D.L., Chan, E.Y., Gritsenko, M.A., Qian, W., Stastna, M. et al. (2005) Proteome analysis of liver cells expressing a full-length hepatitis C virus replicon and biopsy specimens of posttransplantation liver from HCV-infected patients. J Virol 79: 7558-7569.
52. Jacobson, I.M., Brown, Jr R.S., Freilich, B., Afdhal, N., Kwo, P.Y., Santoro, J. et al. (2007) Peginterferon alfa-2b and weight-based or flat dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 46: 971-981.
53. Jeffers, L.J., Cassidy, W., Howell, C.D., Hu, S. and Reddy, K.R. ( 2004) Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39: 1702-1708.
54. Jensen, D.M., Morgan, T.R., Marcellin, P., Pockros, P.J., Reddy, K.R., Hadziyannis, S.J. et al. (2006) Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 43: 954-960.
55. Jianwu, Y., Shuchen, L. and Gui-Qiang, W. ( 2006) Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Liver Int 26: 166-172.
56. Kim, W.R. ( 2002) The burden of hepatitis C in the United States. Hepatology 5(Suppl. 1): S30-S34
57. Khuroo, M.S., Khuroo, M.S. and Dahab, S.T. ( 2004) Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther 20: 931-938.
58. Knodell, R., Ishak, K., Black, W., Chen, T.S., Craig, R., Kaplowitz, N. et al. (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1: 431-435.
59. Koyama, R., Arase, Y., Ikeda, K., Suzuki, F., Suzuki, Y., Saitoh, S. et al. (2006) Efficacy of interferon therapy in elderly patients with chronic hepatitis C. Intervirology 49: 121-126.
60. Kremer, M., Hines, I.N., Milton, R.J. and Wheeler, D. ( 2006) Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis. Hepatology 44: 216-227.
61. Lam, N.P., Neumann, A.U., Gretch, D.R., Wiley, T.E., Perelson, A.S. and Layden, T.J. ( 1997) Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 26: 226-231.
62. Larrea, E., Garcia, N., Qian, C., Civeira, M.P. and Prieto, J. ( 1996) Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 23: 210-217.
63. Layden, J.E., Layden, T.J., Reddy, K.R., Levy-Drummer, R.S., Poulakos, J. and Neumann, A.U. ( 2002a) First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat 9: 340-345.
64. Layden, T.J., Layden, J.E., Reddy, K.R., Levy-Drummer, R.S., Poulakos, J. and Neumann, A.U. ( 2002b) Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. J Viral Hepat 9: 334-339.
65. Layden-Almer, J.E., Ribeiro, R.M., Wiley, T., Perelson, A.S. and Layden, T.J. ( 2003) Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 37: 1343-1350.
66. Lebray, P., Zylberberg, H., Hue, S., Poulet, B., Carnot, F., Martin, S. et al. (2004) Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C. J Viral Hepat 11: 175-182.
67. Liang, T.J., Rehermann, B., Seeff, L.B. and Hoofnagle, J.H. ( 2000) Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132: 296-305.
68. Magalini, A., Puoti, M., Putzolu, V., Quiros-Roldan, E., Forleo, M.A., Rossi, S. et al. (2000) Decrease of HCV RNA after three days of daily interferon treatment is predictive of the virological response at one month. J Clin Lab Anal 14: 120-124.
69. Mangia, A., Minerva, N., Bacca, D., Cozzolongo, R., Ricci, G.L., Carretta, V. et al. (2008) Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 47: 43-50.
70. Mangia, A., Santoro, R., Minerva, N., Ricci, G.L., Carretta, V., Persico, M. et al. (2005) Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352: 2609-2617.
71. Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R. et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358: 958-965.
72. Marcellin, P., Boyer, N., Gervais, A., Martinot, M., Pouteau, M., Castelnau, C. et al. (1997) Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 127: 875-881.
73. Mattioli, B., Straface, E., Quaranta, M.G., Giordani, L. and Viora, M. ( 2005) Leptin promotes differentiation and survival of human dendritic cells and licenses them for Th 1 priming. J Immunol 174: 6820-6828.
74. McCaughan, G.W. and George, J. ( 2004) Fibrosis progression in chronic hepatitis C virus infection. Gut 53: 318-321.
75. McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee, W.M., Rustgi, V.K. et al. (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339: 1485-1492.
76. McHutchison, J.G., Manns, M., Patel, K., Poynard, T., Lindsay, K.L., Trepo, C. et al. (2002) Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123: 1061-1069.
77. McHutchison, J.G., Poynard, T., Pianko, S., Gordon, S.C., Reid, A.E., Dienstag, J. et al. (2000) The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 119: 1317-1323.
78. Mehta, S.H., Brancati, F.L., Sulkowski, M.S., Strathdee, S.A., Szklo, M. and Thomas, D.L. ( 2000) Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 133: 592-599.
79. Missiha, S., Heathcote, J., Arenovich, T. and Khan, K. ( 2007) Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 102: 2181-2188.
80. Muir, A.J., Bornstein, J.D. and Killenberg, P.G. ( 2004) Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350: 2265-2271.
81. Muhlbauer, M., Bosserhoff, A.K., Hartmann, A., Thasler, W.E., Weiss, T.S., Herfarth, H. et al. (2003) A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 125: 1085-1093.
82. Mulhall, B.P. and Younossi, Z. ( 2005) Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol 39: S23-S27.
83. Napoli, J., Bishop, G.A., McGuinness, P.H., Painter, D.M. and McCaughan, G.W. ( 1996) Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 24: 759-765.
84. National Institutes of Health. (2002) Consensus Development Conference on Hepatitis C. Hepatology 36: S3-S120.
85. Nelson, D.R., Davis, G.L., Jacobson, I., Everson, G.T., Fried, M.W., Harrison, S.A. et al. (2009) Hepatitis C virus: a critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol 7: 397-414; quiz 366.
86. Neumann, A.U., Lam, N.P., Dahari, H., Davidian, M., Wiley, T.E., Mika, B.P. et al. (2000) Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 182: 28-35.
87. Neumann, A.U., Lam, N.P., Dahari, H., Gretch, D.R., Wiley, T.E., Layden, T.J. et al. (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282: 103-107.
88. Niederau, C., Lange, S., Heintges, T., Erhardt, A., Buschkamp, M., Hurter, D. et al. (1998) Prognosis of chronic hepatitis C: results of a large prospective cohort study. Hepatology 28: 1687-1695.
89. Ortiz, V., Berenguer, M., Rayon, J.M., Carrasco, D. and Berenguer, J. ( 2002) Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 97: 2408-2414.
90. Olynyk, J.K., Reddy, K.R., Di Bisceglie, A.M., Jeffers, L.J., Parker, T.I., Radick, J.L. et al. (1995) Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 108: 1104-1109.
91. Osterberg, L. and Blaschke, T. ( 2005) Adherence to medication. N Engl J Med 353: 487-497.
92. Palmer, C., Corpuz, T., Guirguis, M., O'Toole, S., Yan, K., Bu, Y.M. et al. (2009) The effect of obesity on intrahepatic cytokine and chemokine expression in chronic hepatitis C infection. Gut Mar 15.
93. Pascu, M., Martus, P., Hohne, M., Wiedenmann, B., Hopf, U., Schreier, E. et al. (2004) Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 53: 1345-1351.
94. Pawlotsky, J.M. ( 2006) Hepatitis C virus population dynamics during infection. Curr Top Microbiol Immunol 299: 261-284.
95. Pawlotsky, J.M. ( 2003) Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis 7: 45-66.
96. Pearlman, B.L., Ehleben, C. and Saifee, S. ( 2007) Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1- infected slow responders. Hepatology 46: 1688-1694.
97. Persico, M., Capasso, M., Russo, R., Persico, E., Croce‘, L., Tiribelli, C. et al. (2008) Elevated expression and polymorphisms of SOCS 3 influence patient response to antiviral therapy in chronic hepatitis C. Gut 57: 507-515.
98. Piche, T., Vandenbos, F., Abakar-Mahamat, A., Vanbiervliet, G., Barjoan, E.M., Calle, G. et al. (2004) The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepat 11: 91-96.
99. Pilli, M., Zerbini, A., Penna, A., Orlandini, A., Lukasiewicz, E., Pawlotsky, J.M. et al. (2007) HCVspecific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology 133: 1132-1143.
100. Poynard, T., Marcellin, P., Lee, S.S., Niederau, C., Minuk, G.S., Ideo, G. et al. (1998) Randomized trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352: 1426-1432.
101. Poynard, T., Bedossa, P., Chevallier, M., Mathurin, P., Lemonnier, C., Trepo, C. et al. (1995) A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 332: 1457-1462.
102. Poynard, T., Bedossa, P. and Opolon, P. ( 1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349: 825-832.
103. Poynard, T., McHutchison, J., Goodman, Z., Ling, M.H. and Albrecht, J. ( 2000) Is an ‘a la carte’ combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 31: 211-218.
104. Powell, E.E., Edwards-Smith, C.J., Hay, J.L., Clouston, A.D., Crawford, D.H., Shorthouse, C. et al. (2000) Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31: 828-833.
105. Ratziu, V., Trabut, J.B. and Poynard, T. ( 2004) Fat, diabetes, and liver injury in chronic hepatitis C. Curr Gastroenterol Rep 6: 22-29.
106. Reddy, K.R., Hoofnagle, J.H., Tong, M.J., Lee, W.M., Pockros, P., Heathcote, E.J. et al. (1999) Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 30: 787-793.
107. Reddy, K.R., Messinger, D., Popescu, M. and Hadziyannis, S.J. ( 2008) Treatment with Peginterferon-alpha2a and ribavarin in older HCV genotype 1 patients with positive prognostic factors leads to high rates of sustained virological response. J Hepatol 48(Suppl. 2): 310A.
108. Rhodes, S.L., Erlich, H., Im, K.A., Wang, J., Li, J., Bugawan, T., Jeffers, L. et al. (2008) Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection. Genes Immun 9: 328-333.
109. Rodriguez-Torres, M., Jeffers, L.J., Sheikh, M.Y., Rossaro, L., Ankoma-Sey, V., Hamzeh, F.M. et al. (2009) Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 360: 257-267.
110. Rodriguez-Torres, M., Rios-Bedoya, C.F., Rodriguez-Orengo, J., Fernández-Carbia, A., Marxuach-Cuétara, A.M., López-Torres, A. et al. (2006) Progression to cirrhosis in Latinos with chronic hepatitis C: differences in Puerto Ricans with and without human immunodeficiency virus coinfection and along gender. J Clin Gastroenterol 40: 358-366.
111. Rodriguez-Torres, M. ( 2008) Latinos and chronic hepatitis C: a singular population. Clin Gastroenterol Hepatol 6: 484-490.
112. Romero-Gomez, M., Montes-Cano, M.A., Otero Fernandez, M.A., Torres, B., Sánchez-Muñoz, D., Aguilar, F. et al. (2004) SLC11A1 promoter gene polymorphisms and fibrosis progression in chronic hepatitis C. Gut 53: 446-450.
113. Romero-Gomez, M., Del Mar Viloria, M., Andrade, R.J., Salmeron, J., Diago, M., Fernandez-Rodriguez, C.M. et al. (2005) Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128: 636-641.
114. Rubbia-Brandt, L., Fabris, P., Paganin, S., Leandro, G., Male, P.J., Giostra, E. et al. (2004) Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 53: 406-412.
115. Sanchez-Tapias, J.M., Diago, M., Escartin, P., Enriquez, J., Romero-Gomez, M., Barcena, R. et al. (2006) Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 131: 451-460.
116. Sarasin-Filipowicz, M., Oakeley, E.J., Duong, F.H., Christen, V., Terracciano, L., Filipowicz, W. et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 105: 7034-7039.
117. Shiffman, M.L. ( 2006) Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders. Curr Gastroenterol Rep 8: 46-52.
118. Shiffman, M.L., Suter, F., Bacon, B.R., Nelson, D., Harley, H., Sola, R. et al. (2007 a) Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 357: 124-134.
119. Shiffman, M.L., Mihas, A.A., Millwala, F., Sterling, R.K., Luketic, V.A., Stravitz, R.T. et al. (2007 b) Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. Am J Gastroenterol 102: 761-766.
120. Shintani, Y., Fujie, H., Miyoshi, H., Tsutsumi, T., Tsukamoto, K., Kimura, S. et al. (2004) Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 126: 840-848.
121. Simpson, S.H., Eurich, D.T., Majumdar, S.R., Padwal, R.S., Tsuyuki, R.T., Varney, J. and Johnson, J.A. ( 2006) A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 333: 15.
122. Singal, A.K. and Anand, B.S. ( 2007) Mechanisms of synergy between alcohol and hepatitis C virus. J Clin Gastroenterol 41: 761-772.
123. Sonzogni, L., Silvestri, L., de Silvestri, A., Gritti, C., Foti, L., Zavaglia, C. et al. (2002) Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. Hepatology 36: 195-201.
124. Steinman, L., Conlon, P., Maki, R. and Foster, A. ( 2003) The intricate interplay among body weight, stress, and the immune response to friend or foe. J Clin Invest 111: 183-185.
125. Strnad, P., Lienau, T.C., Tao, G.Z., Lazzeroni, L.C., Stickel, F., Schuppan, D. et al. (2006) Keratin variants associate with progression of fibrosis during chronic hepatitis C infection. Hepatology 43: 1354-1363.
126. Strader, D.B., Wright, T., Thomas, D.L. and Seeff, L.B. ( 2004) Diagnosis, management and treatment of hepatitis C. Hepatology 39: 1147-1171.
127. Su, X., Yee, L.J., Im, K., Rhodes, S.L., Tang, Y., Tong, X. et al. (2008) Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J Hepatol 49: 184-191.
128. Tai, A.W. and Chung, R.T. (2009) Treatment failure in hepatitis C: mechanisms of non-response. J Hepatol 50: 412-420.
129. Taylor, M.W., Tsukahara, T., Brodsky, L., Schaley, J., Sanda, C., Stephens, M.J. et al. (2007) Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol 81: 3391-3401.
130. Terranova, R. and Luca, S. ( 1996) Preliminary results of beta-interferon treatment in the elderly. Control Clin Trials 17: 123-129.
131. Thuluvath, P.J. and John, P.R. ( 2003) Association between hepatitis C, diabetes mellitus, and race. a case-control study. Am J Gastroenterol 98: 438-441.
132. Walsh, M.J., Jonsson, J.R., Richardson, M.M., Lipka, G.M., Purdie, D.M., Clouston, A.D. et al. (2006) Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 55: 529-535.
133. Wong, J.B., McQuillan, G.M., McHutchison, J.G. and Poynard, T. ( 2000) Estimating hepatitis C morbidity, mortality and costs in the United States. Am J Public Health 90: 1562-1569.
134. Wozniak, M.A., Itzhaki, R.F., Faragher, E.B., James, M.W., Ryder, S.D., Irving, W.L. et al. (2002) Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology 36: 456-463.
135. Zein, C.O., Levy, C., Basu, A. and Zein, N.N. ( 2005) Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol 100: 48-55.
136. Zeuzem, S., Buti, M., Ferenci, P., Sperl, J., Horsmans, Y., Cianciara, J. et al. (2006) Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44: 97-103.
137. Zeuzem, S., Herrmann, E., Lee, J.H., Fricke, J., Neumann, A.U., Modi, M. et al. (2001) Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 120: 1438-1447.
138. Zeuzem, S., Schmidt, J.M., Lee, J.H., Ruster, B. and Roth, W.K. ( 1996) Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 23: 366-371.